

DEPARTMENT OF LABORATORY MEDICINE



MEDICAL UNIVERSITY
OF VIENNA



Vienna Healthcare Group
University Hospital Vienna

2nd October 2024, 12.30 pm

KILM Lecture
**Overcoming Obesity:
the Discovery of
Multi Receptor Drugs**

Lecture Hall (Hörsaalzentrum), Floor 7
Medical University Vienna/University Hospital Vienna
Währinger Gürtel 18-20, 1090 Vienna

labormedizin.meduniwien.ac.at/lecture_tschoep



Matthias Tschöp

Helmholtz Munich
Technical University of Munich

Matthias Tschöp, MD, trained at Ludwig Maximilian University in Munich. After a research fellowship at Eli Lilly in the 1990s, he joined the University of Cincinnati where he advanced to Research Director and Endowed Chair of Medicine. In 2011, he was jointly recruited back to Germany by Helmholtz Munich and the Technical University of Munich, where he holds an Alexander von Humboldt Professorship. Today he also serves as CEO of Helmholtz Munich and Vice President of the Helmholtz Association. Multiple awards include the Heinrich Wieland Prize and the Banting Medal.

Matthias Tschöp is internationally renowned for the first highly effective drugs for human treatment of obesity. Following his discovery of the human hunger hormone, ghrelin, he unraveled fundamental gut-brain signals to discover medicines to safely normalize body weight in close collaboration with the chemist Richard DiMarchi, the dual and triple gut hormone co-agonists. Tirzepatide (Mounjaro®, Zepbound®) is the first representative drug in this class that is FDA-approved. Numerous other versions (Retatrutide, Survodutide etc.) are progressing in late-stage clinical trials. These new medicines present the prospect for reversing the joint pandemics of obesity and diabetes.

Registration:

labormedizin.meduniwien.ac.at/lecture_tschoep

